HRP20171783T1 - Derivati imidazopirazinona - Google Patents
Derivati imidazopirazinona Download PDFInfo
- Publication number
- HRP20171783T1 HRP20171783T1 HRP20171783TT HRP20171783T HRP20171783T1 HR P20171783 T1 HRP20171783 T1 HR P20171783T1 HR P20171783T T HRP20171783T T HR P20171783TT HR P20171783 T HRP20171783 T HR P20171783T HR P20171783 T1 HRP20171783 T1 HR P20171783T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- stereoisomers
- atoms
- tautomers
- formula
- Prior art date
Links
- MPWOBEOETVOESI-UHFFFAOYSA-N imidazo[4,5-b]pyrazin-2-one Chemical class N1=CC=NC2=NC(=O)N=C21 MPWOBEOETVOESI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Lubricants (AREA)
- Developing Agents For Electrophotography (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (11)
1. Spojevi s formulom I
[image]
naznačeni time da
R1 označava H ili metil,
R2 označava A ili Het,
A označava nerazgranati ili razgranati alkil s 1 - 8 C-atoma, pri čemu jedna ili dvije ne-susjedne CH- i/ili CH2-skupine mogu biti zamijenjene s N- ili O-atomima i/ili pri čemu 1-7 H-atoma mogu biti zamijenjeni s F ili Cl,
Het označava pirimidil, piridil, piridazinil, pirazinil, piperidinil, pirolidinil, pirazolil, tiazolil, imidazolil, furanil, tiofenil, pirolil, oksazolil, triazolil, oksadiazolil ili tiadiazolil, svaki od kojih je nesupstituiran ili mono- ili disupstituiran s Hal, A, CN, OH i/ili OA,
Hal označava F, Cl, Br ili I,
pod uvjetom da, ako R1 je H, tada R2 nije 4-OMe,
i njihove farmaceutski prihvatljive soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
2. Spojevi prema zahtjevu 1, naznačeni time da
A označava nerazgranati ili razgranati alkil s 1 - 8 C-atoma, pri čemu jedna ili dvije ne-susjedne CH2-skupine mogu biti zamijenjene s O-atomima i/ili pri čemu 1-3 H-atoma mogu biti zamijenjeni s F, te njihovi farmaceutski prihvatljivi solvati, soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
3. Spojevi prema zahtjevu 1 ili 2, naznačeni time da
Het označava pirimidil, piridil, piridazinil, pirazinil, piperidinil, pirolidinil, pirazolil, tiazolil, imidazolil, furanil, tiofenil, pirolil, oksazolil, triazolil, oksadiazolil ili tiadiazolil, svaki od kojih je nesupstituiran ili monosupstituiran s A,
i njihovi farmaceutski prihvatljivi solvati, soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
4. Spojevi prema zahtjevu 1, naznačeni time da
R1 označava H ili metil,
R2 označava A ili Het,
A označava nerazgranati ili razgranati alkil s 1 - 8 C-atoma, pri čemu jedna ili dvije ne-susjedne CH2-skupine mogu biti zamijenjene s O-atomima i/ili pri čemu 1-3 H-atomi mogu biti zamijenjeni s F,
Het označava pirimidil, piridil, piridazinil, pirazinil, piperidinil, pirolidinil, pirazolil, tiazolil, imidazolil, furanil, tiofenil, pirolil, oksazolil, triazolil, oksadiazolil ili tiadiazolil, svaki od kojih je nesupstituiran ili monosupstituiran s A,
i njihove farmaceutski prihvatljive soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
5. Spojevi prema zahtjevu 1, naznačeni time da su odabrani iz skupine koja sadrži
[image]
i njihovi farmaceutski prihvatljivi solvati, soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
6. Postupak za pripremanje spojeva s formulom I prema zahtjevima 1-5 i njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, naznačen time da
spoj s formulom II
[image]
u kojoj R1 i R2 imaju značenja navedena u zahtjevu 1, je debenziliran,
i/ili
baza ili kiselina s formulom I se pretvara u jednu njihovih soli.
7. Lijekovi naznačeni time da sadrže barem jedan spoj s formulom I prema zahtjevu 1 i/ili njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima, i proizvoljno farmaceutski prihvatljiv nosač, pomoćno sredstvo ili prijenosnik.
8. Spojevi s formulom I prema zahtjevu 1 i njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima, naznačeni time da su za uporabu za liječenje i/ili sprječavanje raka, multiple skleroze, kardiovaskularnih bolesti, ozljeda središnjeg živčanog sustava i različitih oblika upala.
9. Spojevi prema zahtjevu 8 naznačeni time da su za uporabu za liječenje i/ili sprječavanje bolesti odabranih iz skupine koju čine rak glave, vrata, oka, usta, grla, jednjaka, bronha, grkljana, ždrijela, prsa, kosti, pluća, debelog crijeva, rektuma, želuca, prostate, mokraćnog mjehura, uterine, grlića maternice, dojke, jajnika, testisa ili drugih reproduktivnih organa, kože, štitnjače, krvi, limfnih čvorova, bubrega, jetre, gušterače, mozga, središnjeg živčanog sustava, solidnih tumora i tumora krvi.
10. Lijekovi naznačeni time da sadrže barem jedan spoj s formulom I prema zahtjevu 1 i/ili njihove farmaceutski prihvatljive soli, solvati i stereoizomeri, uključujući njihove smjese u svim omjerima, te barem jedan dodatni aktivni sastojak lijeka.
11. Komplet (kit) naznačen time da sadrži odvojena pakiranja
(a) učinkovite količine spoja s formulom I prema zahtjevu 1 i/ili njegove farmaceutski prihvatljive soli, solvati i stereoizomeri, uključujući njihove smjese u svim omjerima, i
(b) učinkovite količine dodatnog aktivnog sastojka lijeka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13006052 | 2013-12-23 | ||
| PCT/EP2014/003226 WO2015096884A1 (en) | 2013-12-23 | 2014-12-03 | Imidazopyrazinone derivatives |
| EP14808506.1A EP3087076B1 (en) | 2013-12-23 | 2014-12-03 | Imidazopyrazinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171783T1 true HRP20171783T1 (hr) | 2017-12-29 |
Family
ID=49916790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171783TT HRP20171783T1 (hr) | 2013-12-23 | 2017-11-16 | Derivati imidazopirazinona |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9718826B2 (hr) |
| EP (1) | EP3087076B1 (hr) |
| JP (1) | JP6446461B2 (hr) |
| KR (1) | KR20160101188A (hr) |
| CN (1) | CN105829317B (hr) |
| AU (1) | AU2014372896B2 (hr) |
| CA (1) | CA2934663A1 (hr) |
| DK (1) | DK3087076T3 (hr) |
| ES (1) | ES2654403T3 (hr) |
| HR (1) | HRP20171783T1 (hr) |
| HU (1) | HUE037606T2 (hr) |
| IL (1) | IL246406A0 (hr) |
| LT (1) | LT3087076T (hr) |
| MX (1) | MX364859B (hr) |
| NO (1) | NO3087076T3 (hr) |
| PL (1) | PL3087076T3 (hr) |
| PT (1) | PT3087076T (hr) |
| RS (1) | RS56746B1 (hr) |
| RU (1) | RU2672885C2 (hr) |
| SG (1) | SG11201605189YA (hr) |
| SI (1) | SI3087076T1 (hr) |
| TW (1) | TWI637956B (hr) |
| WO (1) | WO2015096884A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN108403697A (zh) * | 2018-05-02 | 2018-08-17 | 吉林大学 | 吡嗪酮类小分子抑制剂在制备抗肿瘤药物中的应用 |
| WO2020049017A1 (en) * | 2018-09-07 | 2020-03-12 | Merck Patent Gmbh | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| JP7433403B1 (ja) | 2022-12-06 | 2024-02-19 | 本田技研工業株式会社 | 内燃機関及び鞍乗型車両 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| WO2011089400A1 (en) * | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
| NZ630489A (en) | 2012-03-28 | 2016-04-29 | Merck Patent Gmbh | Bicyclic pyrazinone derivatives |
| RS55062B1 (sr) * | 2012-05-04 | 2016-12-30 | Merck Patent Gmbh | Pirolotriazinon derivati |
-
2014
- 2014-12-03 AU AU2014372896A patent/AU2014372896B2/en not_active Ceased
- 2014-12-03 HU HUE14808506A patent/HUE037606T2/hu unknown
- 2014-12-03 CN CN201480070682.1A patent/CN105829317B/zh not_active Expired - Fee Related
- 2014-12-03 RU RU2016130148A patent/RU2672885C2/ru active
- 2014-12-03 LT LTEP14808506.1T patent/LT3087076T/lt unknown
- 2014-12-03 PT PT148085061T patent/PT3087076T/pt unknown
- 2014-12-03 DK DK14808506.1T patent/DK3087076T3/da active
- 2014-12-03 WO PCT/EP2014/003226 patent/WO2015096884A1/en active Application Filing
- 2014-12-03 CA CA2934663A patent/CA2934663A1/en not_active Abandoned
- 2014-12-03 ES ES14808506.1T patent/ES2654403T3/es active Active
- 2014-12-03 SG SG11201605189YA patent/SG11201605189YA/en unknown
- 2014-12-03 KR KR1020167020018A patent/KR20160101188A/ko not_active Application Discontinuation
- 2014-12-03 US US15/107,211 patent/US9718826B2/en active Active
- 2014-12-03 PL PL14808506T patent/PL3087076T3/pl unknown
- 2014-12-03 JP JP2016542145A patent/JP6446461B2/ja not_active Expired - Fee Related
- 2014-12-03 RS RS20171341A patent/RS56746B1/sr unknown
- 2014-12-03 SI SI201430528T patent/SI3087076T1/en unknown
- 2014-12-03 NO NO14808506A patent/NO3087076T3/no unknown
- 2014-12-03 EP EP14808506.1A patent/EP3087076B1/en active Active
- 2014-12-03 MX MX2016008042A patent/MX364859B/es active IP Right Grant
- 2014-12-22 TW TW103144858A patent/TWI637956B/zh not_active IP Right Cessation
-
2016
- 2016-06-22 IL IL246406A patent/IL246406A0/en active IP Right Grant
-
2017
- 2017-11-16 HR HRP20171783TT patent/HRP20171783T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3087076A1 (en) | 2016-11-02 |
| KR20160101188A (ko) | 2016-08-24 |
| TWI637956B (zh) | 2018-10-11 |
| CA2934663A1 (en) | 2015-07-02 |
| MX2016008042A (es) | 2016-09-16 |
| SG11201605189YA (en) | 2016-07-28 |
| LT3087076T (lt) | 2017-12-27 |
| ES2654403T3 (es) | 2018-02-13 |
| NO3087076T3 (hr) | 2018-02-24 |
| HUE037606T2 (hu) | 2018-09-28 |
| RU2016130148A (ru) | 2018-01-30 |
| AU2014372896A1 (en) | 2016-08-04 |
| US9718826B2 (en) | 2017-08-01 |
| IL246406A0 (en) | 2016-08-31 |
| JP6446461B2 (ja) | 2018-12-26 |
| MX364859B (es) | 2019-05-09 |
| EP3087076B1 (en) | 2017-09-27 |
| US20170002010A1 (en) | 2017-01-05 |
| RU2672885C2 (ru) | 2018-11-20 |
| CN105829317B (zh) | 2019-03-29 |
| PL3087076T3 (pl) | 2018-01-31 |
| WO2015096884A1 (en) | 2015-07-02 |
| CN105829317A (zh) | 2016-08-03 |
| SI3087076T1 (en) | 2018-01-31 |
| RU2016130148A3 (hr) | 2018-07-25 |
| DK3087076T3 (da) | 2017-11-13 |
| PT3087076T (pt) | 2018-01-03 |
| TW201605862A (zh) | 2016-02-16 |
| JP2017500353A (ja) | 2017-01-05 |
| AU2014372896B2 (en) | 2018-08-16 |
| RS56746B1 (sr) | 2018-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171783T1 (hr) | Derivati imidazopirazinona | |
| HRP20200180T1 (hr) | Derivati (aza-)izokinolinona | |
| HRP20171053T1 (hr) | Derivati oksokinazolinil-butanamida | |
| HRP20161033T1 (hr) | Derivati pirolotriazinona | |
| JP2015529229A5 (hr) | ||
| JP2015511609A5 (hr) | ||
| JP2015515961A5 (hr) | ||
| RU2015115278A (ru) | Производные гидропирролопиррола для применения в качестве ингибиторов синтазы жирных кислот | |
| JP2015524450A5 (hr) | ||
| CN105008343B (zh) | 作为选择性雌激素受体降解剂的苯并噻吩衍生物及其组合物 | |
| JP2018510191A5 (hr) | ||
| JP2020097596A5 (hr) | ||
| RU2016147727A (ru) | Гетероциклилбутанамидные производные | |
| JP2015529234A5 (hr) | ||
| JP2017160216A (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| JP2014509659A5 (hr) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2010539098A5 (hr) | ||
| CN101528716A (zh) | 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 | |
| HRP20141034T1 (hr) | Spojevi koji sadrže (s)-2-amino-1-(4-klorofenil)-1-[4-(1h-pirazol-4-il)-fenil]-etanol kao modulator proteinskih kinaza | |
| SI3030554T1 (en) | PIPERIDIN-SEA DERIVATIVES | |
| HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
| JP2014512355A5 (hr) | ||
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| RU2014141934A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями |